secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001062822-25-000003
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon appoints Scott M. Coiante as CFO; base salary $450K, option for 230K shares
--------------------------------------------------------------------------------

- Scott M. Coiante named SVP and CFO effective Jan 2, 2025; Kristen Alexander remains principal accounting officer.
- Base salary $450K; annual cash bonus target 40% of base salary.
- Granted option to purchase 230K shares vesting 25% after 1 year then 1/48th monthly.
- Coiante previously CFO at Agile Therapeutics and Aprea Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/0001062822-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000003/lxrx-20250102.htm
  HTML page:      https://secwatch.observer/filing/0001062822-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer